Free Newsletter
Combo vaccines endorsed by federal advisory panel
In a move that should make it easier for millions of children in the U.S. to get their recommended vaccinations, a federal vaccine advisory panel has endorsed two new combination vaccinations. GlaxoSmithKline won a thumb's up from the advisory panel for a four-in-one shot that guards against diphtheria, tetanus, pertussis and polio at a cost of $45. Sanofi Pasteur won an endorsement of its five-in-one shot for diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b, or HiB. That jab costs $69. The vaccine advisory panel's decision helps clear the way for 36 million children to receive the vaccines through the Vaccines for Children program. Both vaccines have been approved by the FDA.
The new combination vaccines don't change the number of vaccinations that children are expected to receive. But it should make it easier for parents to keep track of which vaccinations have been completed.
- read the report in the Baltimore Sun
Comments
I was employed for many years in Pediatric Care for children at risk, 0-3 yrs. old. Many cases of autism, retardation & seizure were due to chemical reactions to "childhood immunizations". Big Pharm is raking in the money while children are suffering & growing up to be a burden on society because they cannot function as adults thanks to childhood immunizations!
thats a really big statement your making here
there has not been any documented evidence associating thiomersal or mercury content in the vaccines with autism even though there has been a big fuss about it
these vaccines save millions of lives globally lets catharize ourselves on something else ))
Susan,
Check the scientific literature before taking such broad swipes. Your "employment" (whatever that means) in pediatric care makes you no more knowledgeable about the subject than a gas station attendant is at designing race cars. There is not one ounce of scientific research that supports your notion. Yet, because of this hysteria, literally millions of dollars have been spent investigating this frivolous, unfounded claim. That money could have been much better spent on any number of children's health topices, even autism.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




